Deutsche Bank AG Grows Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Deutsche Bank AG raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,037,077 shares of the company’s stock after purchasing an additional 70,690 shares during the quarter. Deutsche Bank AG owned about 0.21% of Elanco Animal Health worth $12,559,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health during the fourth quarter valued at about $29,000. Crestline Management LP grew its stake in Elanco Animal Health by 19.7% in the fourth quarter. Crestline Management LP now owns 105,013 shares of the company’s stock worth $1,272,000 after purchasing an additional 17,317 shares in the last quarter. Cetera Investment Advisers grew its stake in Elanco Animal Health by 17.2% in the fourth quarter. Cetera Investment Advisers now owns 31,004 shares of the company’s stock worth $375,000 after purchasing an additional 4,553 shares in the last quarter. Centiva Capital LP acquired a new position in Elanco Animal Health in the fourth quarter worth about $1,188,000. Finally, Brevan Howard Capital Management LP grew its stake in Elanco Animal Health by 93.9% in the fourth quarter. Brevan Howard Capital Management LP now owns 100,235 shares of the company’s stock worth $1,214,000 after purchasing an additional 48,545 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ELAN shares. Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, Stifel Nicolaus lifted their price target on Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health has an average rating of “Hold” and an average price target of $15.00.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $12.95 on Friday. The firm’s 50-day moving average is $10.05 and its 200-day moving average is $11.45. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $6.43 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 earnings per share. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.